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BRIEF DEFINITIVE REPORT
        Multiple sclerosis (MS) is an infl  ammatory, de-
myelinating disease of the central nervous sys-
tem, believed to be initiated and mediated by 
autoreactive T cells directed against myelin anti-
gens. It develops in young adults with a complex 
genetic predisposition and is thought to require 
an inciting environmental insult such as a viral 
infection to trigger the disease (  1  ). So far, EBV 
stands out as the infectious agent for which there 
is the most compelling evidence for an associa-
tion with MS (  2  –  7  ). 
  The evidence implicating EBV in MS 
develop  ment includes the observation that in-
dividuals with a history of symptomatic primary 
EBV infection or infectious mononucleosis have 
a more than twofold increased risk of develop-
ing MS compared with subjects who acquired 
EBV without symptoms (  4, 5  ). Adults and chil-
dren with MS are universally, i.e., nearly 100%, 
seropositive for EBV compared with seroposi-
tivity rates of 90  –  95% in adults (  2, 6  ) and   <  85% 
in age-matched pediatric cohorts (  3  ). In addi-
tion, a marked increase in serum antibody titers 
to EBV nuclear antigens (EBNAs) several years 
before the onset of fi  rst symptoms suggests an 
involvement of EBV early in the pathogenesis 
of MS (  2, 6  ). Finally, EBV-infected B cells have 
recently been found to be signifi  cantly enriched 
in tertiary lymphoid tissues in postmortem brain 
samples from patients with MS, but not in other 
infl  ammatory central nervous system diseases (  8  ). 
  EBV-specifi  c immunity in MS and the mech-
anisms by which EBV infection increases the 
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  Symptomatic primary Epstein-Barr virus (EBV) infection and elevated humoral immune 
responses to EBV are associated with an increased risk of developing multiple sclerosis 
(MS). We explored mechanisms leading to this change in EBV-specifi  c immunity in un-
treated patients with MS and healthy virus carriers matched for MS-associated HLA alleles. 
MS patients showed selective increase of T cell responses to the EBV nuclear antigen 1 
(EBNA1), the most consistently recognized EBV-derived CD4  +   T cell antigen in healthy virus 
carriers, but not to other EBV-encoded proteins. In contrast, infl  uenza and human cyto-
megalovirus  –  specifi  c immune control was unchanged in MS. The enhanced response to 
EBNA1 was mediated by an expanded reservoir of EBNA1-specifi  c central memory CD4  +   
T helper 1 (Th1) precursors and Th1 (but not Th17) polarized effector memory cells. In addi-
tion, EBNA1-specifi  c T cells recognized myelin antigens more frequently than other auto-
antigens that are not associated with MS. Myelin cross-reactive T cells produced IFN-    , 
but differed from EBNA1-monospecifi  c cells in their capability to produce interleukin-2, 
indicative of a polyfunctional phenotype as found in controlled chronic viral infections. Our 
data support the concept that clonally expanded EBNA1-specifi  c CD4  +   T cells potentially 
contribute to the development of MS by cross-recognition of myelin antigens. 
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mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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ELISPOT assays and compared with the virus vector backbone 
(rVV-TK       ) to infl  uenza A virus (A/Aichi/68; H3N2) infec-
tion and to superantigen stimulation (SEB). 
  Among all rVV-EBV antigen constructs and infl  uenza 
products tested in 24 MS patients and 24 healthy EBV carriers, 
EBNA1 was the only diff  erentially recognized T cell antigen 
(  Fig. 1 B  ).   rVV-EBV nuclear antigens were consistently rec-
ognized by both MS patients (20/24 for EBNA3 and 14/24 
for EBNA1) and healthy virus carriers (18/24 for EBNA3 
and 10/24 for EBNA1). The hierarchy of T cell  –  mediated 
latent EBV antigen recognition was preserved in patients and 
controls. EBNA3C-, EBNA3B-, and EBNA3A-specifi  c T 
cells showed estimated precursor frequencies of (means   ±   
SD) 0.023   ±   0.01%, 0.014   ±   0.01%, and 0.011   ±   0.004% 
of PBMCs, respectively. EBNA1-specifi  c IFN-      –  producing 
T cells were detected at frequencies of 0.008   ±   0.002% of 
PBMC in patients with MS and 0.005   ±   0.001% of PBMC in 
healthy virus carriers (P = 0.005). Depletion of CD8  +   T cells 
by magnetic cell separation resulted in a substantial decrease 
or abrogation of most rVV-EBNA3 antigen-specifi  c IFN-     
risk for MS are not well characterized and are poorly under-
stood. We investigated cellular and humoral immune responses 
to a broad panel of EBV-encoded proteins, as well as to other 
ubiquitous viruses, i.e., human cytomegalovirus (HCMV) 
and infl  uenza A virus in 24 untreated patients with MS and 
24 healthy EBV carriers. Our data indicate that EBNA1-spe-
cifi  c CD4  +   Th1 cells are selectively expanded in MS and that 
some of these have the ability to cross-recognize MS-associ-
ated myelin antigens. 
    RESULTS AND DISCUSSION   
  Selective increase of EBNA1-specifi  c T cell responses in MS 
  To evaluate T cell responsiveness to EBV latency gene pro-
ducts in untreated patients with MS versus healthy virus carriers 
(Table S1, available at http://www.jem.org/cgi/content/full/
jem.20072397/DC1), PBMCs were separately infected with 
recombinant vaccinia virus (rVV) constructs expressing the la-
tent EBV nuclear antigens EBNA1, 2, 3A, 3B, 3C, latent mem-
brane protein 1 (LMP1), LMP2A, and the lytic EBV-encoded 
protein BZLF1. Responses were assessed by IFN-      –  specifi  c 
    Figure 1.         Selective increase in rVV-EBNA1 recognition in MS.   PBMCs from 24 MS patients and 24 healthy virus carriers were separately in-
fected with rVV constructs expressing the EBV latent antigens EBNA1, 2, 3A, 3B, 3C, LMP1, and LMP2A, as well as the lytic EBV-encoded protein 
BZLF1. (A) Approximately 10  –  15% of PMBCs infected with the LMP1-encoding rVV consistently showed intracellular expression of LMP1 by fl  ow 
cytometry, indicating that rVVs achieve EBV antigen expression in PBMCs. (B) EBNA1 protein expression in rVV-EBNA1    GA infected PBMCs com-
pared with a fusion protein consisting of the C terminus of EBNA1 (aa 400  –  641) coupled to the heavy chains of an antibody (IgG-EBNA1). (C) IFN-    
specifi  c ELISPOT responses in PBMCs to the indicated EBV antigens, to the virus vector backbone (rVV-TK       ), and to infl  uenza A virus (A/Aichi/68; 
H3N2) infection. Bars represent means. *, P = 0.005. (D) IFN-      – specifi  c ELISPOT responses to the indicated antigens, but in CD8-depleted PBMCs. 
*, P = 0.003.     JEM VOL. 205, August 4, 2008  1765
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CD8  +   T cell proliferation upon stimulation with any of the 
tested antigens did not signifi  cantly diff  er between patients 
and controls (Fig. S2, available at http://www.jem.org/cgi/
content/full/jem.20072397/DC1). These data further indicate 
that EBNA1-specifi  c CD4  +   T cell responses are selectively 
increased in MS. 
  EBNA1-specifi  c T cell subsets refl  ect frequent antigen 
recognition in MS 
  To identify which CD4  +   T cell subsets contribute to the in-
creased response to EBNA1, we determined the phenotype 
of CFSE-diluted T cells using markers indicative for central 
and eff  ector memory compartments (CD45RO, CD62L), co-
stimulation (CD27, CD28), Th1 commitment (CXCR3), 
and homing capacity and recruitment to secondary lymphoid 
organs and infl  amed tissue (CD62L, CXCR3) (  14  ). Nearly 
all proliferating EBNA1-specifi  c CD4  +   T cells in healthy 
virus carriers originated from the memory pool (CD45RO  +  ) 
and consisted of both CD62L  +   central memory (T  CM  ) and 
CD62L    –    eff  ector memory (T  EM  ) T cell subsets (  9, 15, 14  ). 
We have previously shown that EBNA1-specifi  c T cells main-
tain their CD62L surface expression during a 6-d CFSE assay 
(  14  ). As shown in   Fig. 3 A  , both memory compartments 
contributed to increased T cell response to EBNA1 (P = 
0.007 for T  EM   and P = 0.03 for T  CM  ) and the T  EM   expansion 
(2.1-fold) appeared to be slightly higher than T  CM   expansion 
(1.7-fold), indicating frequent antigen recognition in vivo.   
responses, but had only a minimal eff  ect on rVV-EBNA1  –
  specifi  c IFN-     responses in both patients and controls (P = 
0.003;   Fig. 1 C   and Table S2, available at http://www.jem
.org/cgi/content/full/jem.20072397/DC1). In line with this, 
rVV-EBNA1  –  specifi  c IFN-     responses were substantially 
decreased after CD4  +   T cell depletion in a subgroup of 12 
patients and 12 controls, whereas rVV-EBNA3C  –  specifi  c re-
sponses were still detectable in most donors that showed re-
activity to rVV-EBNA3C in PBMCs (Fig. S1). Altogether, 
these data indicate a predominant expansion of the EBNA1-
specifi  c CD4  +   T cell compartment in MS. 
  We previously applied a fl  ow cytometry-based intracellu-
lar IFN-     staining assay to determine ex vivo frequencies of 
T cells specifi  c for EBNA1 and a limited set of MHC class I  –
  restricted EBV epitopes in diff  erent cohorts of MS patients 
and healthy controls. We found the frequencies of EBNA1-
specifi  c CD4  +   T cells to be twofold higher in MS patients 
than healthy virus carriers (0.149 and 0.073% of total CD4  +   
T cells, respectively) (  9  ). Similar to other groups (  10  ), we did 
not detect signifi  cant diff  erences in EBV-specifi  c CD8  +   T 
cell frequencies. EBNA1 is the most consistently recognized 
CD4  +   T cell antigen in healthy virus carriers (  11, 12  ) and 
elevated IgG titers to EBNA1, but not to EBNA2, EBV-
encoded early antigens or the viral capsid antigen, are the 
strongest predictor of MS risk (  2, 6  ). In this study, we extended 
our previous fi  nding to a broad panel of EBV-encoded anti-
gens, showing that EBNA1-specifi  c CD4  +   T cells are indeed 
selectively expanded in MS. 
  To further characterize if enhanced T cell responses se-
lectively target EBNA1 in MS, we compared these to reac-
tivities against other ubiquitous viral antigens. Using a fl  ow 
cytometry-based CFSE-dilution assay, we analyzed EBNA1, 
HCMV-encoded phosphoprotein 65 (pp65)-antigen  –   and 
infl  uenza A virus-specifi  c CD4  +   and CD8  +   T cell responses 
in patients and healthy virus carriers matched for expression of 
MS-associated HLA-DR alleles. Both HCMV and infl  uenza 
are ubiquitous pathogens; HCMV induces a latent infection 
with continuous virus production, and both HCMV-pp65 
stimulation and infl  uenza infection are known to elicit ro-
bust CD4  +   T cell responses (  13  ). Consistent with our data 
on IFN-     secretion to rVV-EBNA1 infection, patients with 
MS showed signifi  cantly higher proliferative responses to the 
C-terminal domain of EBNA1 (aa 400  –  641), toward which 
most of the T cell responses of healthy virus carriers are di-
rected (  Fig. 2 B  ) (  12  ).   EBNA1-specifi  c CD4  +   T cell responses 
were detectable in 75% (18/24) of MS and 66% (16/24) of 
healthy donors, with mean proliferating T cell frequencies of 
6.12   ±   3.2% (MS) and 3.38   ±   1.2% (HD; P = 0.004). CD4  +   
T cell responses to an overlapping peptide library covering 
the entire sequence of the HCMV-encoded pp65 protein (aa 
1  –  561) were detectable in 25% (6/24) of MS and 29% (7/24) 
of healthy donors with similar frequencies of 1.87   ±   1.1% 
(MS) and 1.76   ±   0.7% (HD). Infl  uenza-specifi  c responses were 
detectable in 83% (20/24) of MS and 75% (18/24) of HD 
with frequencies of CFSE-diluted CD4  +   T cells of 7.33   ±   
5.1% (MS) and 10.43   ±   4.4% (HD). CD3  +  CD4       , presumably 
    Figure 2.         Increased CD4  +   T cell proliferation to EBNA1, but not 
HCMV-pp65 or infl  uenza, in MS.   PBMCs from 24 MS patients and 24 
healthy virus carriers were stimulated with overlapping peptide libraries span-
ning the C-terminal domain of EBNA1 (aa 400  –  641), with the entire sequence 
of the HCMV-encoded pp65 protein (aa 1  –  561), and by infl  uenza A virus infec-
tion. Antigen-specifi  c proliferative responses were determined in a fl  ow cytom-
etry  –  based CFSE-dilution assay. (A) An analysis of a representative blood donor. 
(B) Summary of all positive responses. *, P = 0.004. Bars represent means.    1766 EBV IMMUNITY IN MULTIPLE SCLEROSIS   | L  ü  nemann et al. 
EBNA1 in MS might generate a minor population of presum-
ably further diff  erentiated CD4  +   T cells. 
  We had previously reported that EBNA1-specifi  c Th1-
polarized cells predominate the CD4  +   T cell response (  20  ). 
To additionally determine the Th1 versus Th17 lineage com-
mitment of EBNA1-specifi  c T cells, we applied an intracel-
lular cytokine staining assay in CFSE-diluted T cells after 
antigen-specifi  c proliferation. PBMCs from six patients with 
MS and six healthy virus carriers responding to EBNA1, 
were stimulated with purifi  ed   Candida albicans   antigens (  21  ), 
EBNA1, or SEB. After 7 d, cells were restimulated with 
PMA/ionomycin for intracellular IL-17 detection.   C. albicans    –
  stimulated CD4  +   T cells produced IL-17 at mean frequen-
cies of 6.7% of CFSE-diluted cells (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20072397/DC1). 
In contrast, IL-17 could not be detected in any EBNA1-
stimulated T cells, neither in patients with MS nor in healthy 
virus carriers, indicating that deregulated T cell response to 
EBNA1 in MS is mediated by Th1, and not by Th17, cells. 
  Collectively, these data suggest that patients with MS 
show an expanded reservoir of EBNA1-specifi  c T  CM   CD4  +   
Th1 precursors, which might continuously fuel Th1-polarized 
eff  ector cells that display a phenotype indicative of frequent 
antigen recognition and increased homing capacity to sites 
of infl  ammation. 
  Elevated titers and IgG1 polarization of EBNA1-specifi  c 
antibodies in MS 
  To further assess the relative activity of EBNA1-specifi  c Th1 cells 
in vivo, we analyzed EBNA1-targeting IgG isotype-specifi  c 
  CXCR3, the chemokine receptor for CXCL9/MIG, 
CXCL10/IP-10, and CXCL11/I-TAC, is preferentially ex-
pressed on activated Th1 T cells (  15  ) and has been shown to 
play an important role in T cell traffi   cking to infl  amed tissues 
(  16  ). CXCR3 expression is consistently increased on CSF 
versus blood CD4  +   memory T cells and CXCR3  +   T cells 
and its ligand CXCL10/IP-10 are readily detectable in active 
MS lesions ( 17  ). We observed that both proliferating EBNA1-
specifi  c T  CM   and T  EM   cells were predominantly CXCR3  +   
(  Fig. 3 A  ). The increased response in MS resulted from an 
exclusive expansion of CXCR3  +  , but not CXCR3       , CD4  +   
T cells (P = 0.01). 
  The majority of latent EBV antigen-specifi  c CD4  +   and 
CD8  +   memory T cells accumulate within a CD27  +  CD28  +   
diff  erentiation compartment during primary infection and 
remain enriched within this compartment throughout the 
persistent phase of infection (  18  ). CD8  +   T cells specifi  c for 
lytic cycle antigens accumulate within both CD27  +  CD28  +   
and CD27       CD28  +   compartments, indicating diff  ering dif-
ferentiation states and/or co-stimulatory requirements (  18  ). 
The majority of EBNA1-specifi  c T cells in both patients 
and controls were CD27  +   CD28  +   (  Fig. 2 C  ). However, we 
observed that EBNA1-specifi  c CD4  +   T cells of some MS 
patients were enriched in the CD27       CD28  +   compartment 
(  Fig. 3 B  ), which was not detectable in healthy virus carriers. 
Initial up-regulation of CD27 expression upon TCR engage-
ment of CD4  +   T cells is followed by its irreversible loss after 
repeated antigenic stimulation, as observed in terminally dif-
ferentiated memory T cells (  19  ). Our data, therefore, suggest 
that the increased eff  ector and central memory T cell response to 
    Figure 3.         Phenotype of EBNA1-specifi  c T cell subsets is indicative of frequent antigen recognition in MS.   The phenotype of EBNA1-specifi  c T 
cells was assessed on CFSE  low   cells proliferating in response to stimulation with the EBNA1 peptide library by CD27, CD28, CD62L, and CXCR3 fl  ow cyto-
metric staining in 24 MS patients and 24 healthy virus carriers. (A) Frequencies of the indicated subsets in MS patients (MS) and healthy controls (HD). 
(B) Analysis of a representative patient with MS.     JEM VOL. 205, August 4, 2008  1767
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intact in MS patients, resulting in an unchanged EBV load, 
we compared the B cell transformation rate and the inhibition 
of EBV-infected B cell outgrowth in a modifi  ed regression 
assay. CD19  +   selected B cells from 16 patients with MS and 
16 healthy virus carriers were infected with EBV supernatant 
overnight and incubated for 12 d with increasing concentra-
tion of CD19        eff  ector cells. As shown in Fig. S4 (available at 
http://www.jem.org/cgi/content/full/jem.20072397/DC1), 
patients with MS did not diff  er from healthy EBV carriers in 
the rate of EBV-induced B cell transformation or in their abil-
ity to control EBV-infected B cell outgrowth in vitro. Thus, 
although high viral loads that occur during symptomatic pri-
mary infection are associated with an increased risk of de-
veloping MS (  4, 5  ), our data do not provide evidence for an 
increased viral replication or impaired immune control of EBV 
infection in MS during chronic infection. 
  EBNA1-specifi  c CD4  +   T cells recognize myelin antigens 
  EBV-derived epitopes have previously been identifi  ed as 
molecular mimics of immunodominant myelin T cell antigens. 
Wucherpfennig and Strominger (  22  ) and Lang et al. (  23  ) 
characterized an epitope derived from the DNA-polymerase 
protein of EBV (BALF5), which showed strong agonistic 
activity in myelin basic protein (MBP)  –  specifi  c (aa 83  –  99) 
T cells in the context of MS-associated restriction elements. 
However, it is not known whether BALF5-specifi  c immune 
responses are part of the EBV-specifi  c immune control in 
humans, and whether they qualitatively or quantitatively 
diff  er in patients with MS. Because we found that EBNA1-
specifi  c T cells are expanded in MS, we determined the fre-
quency of myelin-recognizing EBNA1-specifi  c T cells using 
a limiting dilution approach as outlined in Fig. S5 (available 
at http://www.jem.org/cgi/content/full/jem.20072397/DC1). 
Based on a precursor frequency of EBNA1-specifi  c CD4  +   
T cells of 5  –  10 per 100,000 circulating mononuclear cells 
(  9, 14  ), PBMCs were seeded at cell concentrations of 12,500, 
25,000, and 50,000 per well in 96-well plates and stimulated 
with peptides covering the C-terminal domain of EBNA1 
responses by ELISA assays with recombinant EBNA1 (  20  ). 
Th1 cytokines are considered to skew antibody responses to-
ward the IgG1 opsonizing and complement-fi  xing immuno-
globulin subclass, and Th2 toward the allergic IgG4 subclass 
(  20  ). As shown in   Fig. 4  , patients with MS showed signifi  -
cantly increased titers of EBNA1-specifi  c IgG1 (P = 0.02), but 
not IgG2 or IgG4.   EBNA1-specifi  c IgG3 antibodies could 
neither be detected in HD, nor in MS patients (unpublished 
data). IgG1 was the most frequently detected isotype in all in-
dividuals tested, refl  ecting the Th1 polarization of EBNA1-
specifi  c T cell immunity. IgG2 and IgG4 responses to EBNA1 
were detected in a minor subgroup of patients and controls 
with no statistically signifi  cant diff  erences between both co-
horts. There were also no diff  erences in the IgG-response to 
HCMV. To further determine whether the increased anti-
body response is selectively skewed toward EBNA1 or refl  ects 
a broadly enhanced humoral immune response to EBV, we 
compared IgG1 responses to a standardized infected B cell ly-
sate that predominantly contains lytic EBV antigens (  18  ). An-
tibody reactivities to EBV-infected cell lysates tended to be 
higher in MS patients, but did not diff  er signifi  cantly between 
both cohorts, indicating a prominent increase of EBNA1-spe-
cifi  c, but not generally of EBV-specifi  c IgG responses in MS. 
Although EBNA1-specifi  c IgG responses have previously been 
described to be prominently elevated in MS (  2, 6  ), we show 
that this increase in humoral immunity to EBNA1 is mediated 
by IgG1 antibodies refl  ecting the Th1 commitment of EBNA1-
specifi  c T cell immunity in MS. 
  Effi  cient regression of EBV-infected B cell outgrowth in MS 
  Selectively deregulated immune responses to EBNA1 in MS 
could result from an increased availability of the viral anti-
gen caused by heightened viral replication. Although there 
is evidence for an association between clinical disease activity 
and EBV reactivation in MS (  7  ), we detected levels of cell-
bound viral genomes in circulating blood cells that were not 
statistically diff  erent from healthy EBV carriers in a cross-
sectional analysis (  9  ). To assess if EBV immune control was 
    Figure 4.         Elevated titers of EBNA1-specifi  c IgG1 antibodies in MS.   EBNA1-specifi  c IgG isotype-specifi  c titers were determined by ELISA and com-
pared with HCMV-EA IgG responses. The presented data summarize 20 MS patients and 16 healthy virus carriers. *, P = 0.02. Error bars represent the SD.     1768 EBV IMMUNITY IN MULTIPLE SCLEROSIS   | L  ü  nemann et al. 
Myelin antigens were derived from 4 major myelin proteins, 
MBP, proteolipid protein, myelin oligodendrocyte glycopro-
tein, and 2    ,3    -cyclic nucleotide 3     phosphodiesterase (Table S3), 
and selected based on careful literature review as immuno-
dominant in humans and/or encephalitogenic in animals (  25  ). 
PIP was chosen because it is a prominent autoantigen ex-
pressed in the target tissue of type 1 diabetes (T1D) and CD4  +   
T cell responses to PIP have been implicated in the patho-
genesis of T1D (  26  ). 
(aa 400  –  641) to obtain single-cell precursors in plates with 
  <  30% positive cultures (  24  ). Single-cell precursor plates were 
restimulated after 10 d and expanded for an additional 12 d in 
the presence of low-dose IL-2 (10 IU/ml) and IL-7 (10 ng/ml). 
At day 22 of culture, EBNA1-specifi  c T cells were trans-
ferred to a new plate and stimulated either with EBNA1, 
myelin antigen-derived peptides (  n   = 15), or peptides (  n   = 30) 
covering the entire sequence of the human proinsulin precursor 
protein (PIP, aa 1  –  110) at equimolar concentrations (1   μ  M). 
    Figure 5.         Autoantigen-recognition of EBNA1-specifi  c T cells.   Cross-reactivity of EBNA1-specifi  c T cells to myelin antigens or proinsulin was ana-
lyzed. (A) Frequencies of EBNA1-specifi  c TCLs generated from 6 patients with MS and 6 healthy EBV carriers recognizing peptides of myelin antigens or 
proinsulin. *, P = 0.01. (B) Frequencies of autoantigen-recognizing EBNA1-specifi  c T cells in MS patients compared with healthy virus carriers. (C) Stimula-
tion indices (SI) after EBNA1 stimulation of EBNA1-monospecifi  c, EBNA1-specifi  c myelin-reactive, and EBNA1-specifi  c insulin-reactive T cells in patients 
and controls. (D) Serological clonality analysis by fl  ow cytometric staining for TCR-V    3, 1, 5S1, 2, 5S2, 5S3, 6S7, 7, 8, 9, 11, 13S1, 12, 13S6, 16, 14, 17, 18, 
1S3, 20, 22, and 23. Depicted are the results for one representative TCR V   3 +   CD4 +   T cell clone. (E) Cytokine profi  le of cross-reactive versus monospecifi  c 
EBNA1-specifi  c T cells. IL-2: *, P   <   0.0001. MIP-1    : *, P = 0.02. Error bars represent the SD.     JEM VOL. 205, August 4, 2008  1769
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oligoclonal CSF IgG are both derived from EBV, i.e., 
EBNA1 and a lytic, less well characterized structural EBV 
protein (BRRF2) (  27  ), suggesting that EBNA1-specifi  c anti-
bodies are not only systemically elevated in MS, but also en-
riched in the CSF. The functional relevance of EBNA1-specifi  c 
antibodies is, however, unclear because EBNA antigens are 
only expressed intracellularly in infected proliferating B cells. 
In contrast, T cells specifi  c for EBNA1 are considered to be 
a crucial component of EBV-specifi  c immune control. CD4  +   
T cells of healthy EBV carriers consistently respond to EBNA1, 
are Th1 in function, recognize autologous EBV-transformed 
B cell lines (B-LCL), and have the capacity to kill EBNA1-
expressing targets via CD95/CD95L (  11, 12, 20  ). In this 
study, we provide evidence that EBNA1-specifi  c CD4  +   Th1 
cells are selectively expanded in MS patients, and that these 
have the ability to cross-recognize MS-associated myelin anti-
gens. Although the frequency of cross-reactive T cells within 
the EBNA1-specifi  c compartment is similar in MS patients 
and controls, we found that the overall number of EBNA1-
specifi  c T cells is increased in MS. Because both patients and 
controls were matched for expression of MS-associated HLA 
alleles, it is tempting to speculate that risk alleles such as HLA-
DRB1*1501 predispose for selection of EBNA1 cross-reactive 
epitopes and that an increased total number of cross-reactive 
EBNA1-specifi  c T cells, generated in a susceptible HLA back-
ground, might contribute to the development of MS. 
  The distinct cytokine signature of cross-reactive CD4  +   T 
cell clones is indicative of polyfunctional T cells, which are 
invariably found in individuals with eff  ective immune con-
trol of chronic HIV-1 or EBV infections (  28, 29  ). Polyfunc-
tional T cells, which probably constitute recent recruits from 
the central memory compartment, diff  er from further diff  er-
entiated eff  ector T cells in their ability to produce IL-2, to 
retain their antigen-specifi  c proliferation capacity and their 
lower functional antigen avidities (  28, 30  ). Being equipped 
with a low-avidity TCR, it has been assumed that they are 
particularly important under conditions of antigen persistence 
and high antigen load because they are less susceptible to 
  exhaustion or activation-induced cell death (  28  ). Consistent 
with these considerations, a more extensive priming of poly-
functional and lower avidity T cells during symptomatic primary 
EBV infection with high levels of viral load, and continuous 
restimulation caused by antigen presence in MS brains (  8  ), 
might establish a larger cross-reactive T cell compartment, 
which could predispose for MS. Such mechanisms could ex-
plain the observation that individuals with a history of infectious 
mononucleosis are at greater risk to develop MS compared 
with subjects who acquired the virus without symptoms 
(  4, 5  ). This scenario might not be restricted to, but become 
most evident, in the context of MS and EBV as a prototypic 
pathogen that requires strong and sustained T cell  –  mediated 
immune control to prevent the occurrence of EBV-associ-
ated malignancies. 
  Although our study provides evidence for a selective dereg-
ulation of EBNA1-specifi  c T cell responses in MS and a poten-
tial pathogenic signifi  cance of polyfunctional EBNA1-specifi  c 
  Under these conditions, the number of EBNA1-specifi  c 
T cells recognizing myelin autoantigens was signifi  cantly 
higher compared with recognition of the control autoantigen 
(P = 0.01). Of a total of 444 EBNA1-specifi  c T cell lines 
(TCLs) generated from 6 patients with MS and 6 healthy 
EBV carriers, 15 showed cross-recognition of myelin anti-
gens corresponding to a precursor frequency of 3.37% myelin 
antigen-recognizing EBNA1-specifi  c CD4  +   T cells (  Fig. 5, 
A and B  ).   Cross-recognition of PIP could be detected in 2 
TCLs only corresponding to a frequency of 0.45% of EBNA1-
specifi  c CD4  +   T cells. Stimulation indices (SI) after EBNA1 
stimulation of EBNA1-monospecifi  c (mean   ±   SEM in MS 
vs. HD: 10.75   ±   0.9 vs. 11.4   ±   1.1; P = 0.09), EBNA1-spe-
cifi  c myelin-reactive (mean   ±   SEM in MS vs. HD: 4.69   ±   
0.9 vs. 4.7   ±   1.1; P = 0.85), and EBNA1-specifi  c insulin-re-
active (mean in MS vs. HD: 3.12 vs. 3.7) T cells did not diff  er 
between patients and controls (  Fig. 5 C  ). SI after myelin an-
tigen stimulation of EBNA1-specifi  c T cells were moderately 
increased in patients (mean   ±   SEM: 2.93   ±   0.19) compared 
with controls (2.17   ±   0.08; P = 0.003). SI after insulin pep-
tide stimulation was 2.9 and 3.4 in 2 TCLs derived form 1 
patient and 1 healthy donor, respectively. Flow cytometric 
analysis of TCR V     chain expression demonstrated that fi  ve 
representative cross-reactive TCLs did not contain more than 
one V     clonotype and were homogenously CD4  +  CD8       , iden-
tifying the cross-reactive TCLs as EBNA1- and myelin-spe-
cifi  c CD4  +   T cell clones. Flow cytometric analysis for one 
V    3  +   CD4  +   T cell clone is shown in   Fig. 5 D  , and other 
clones were positive for V    2 or V    12 or did not stain with 
any of the TCR V     antibodies used (unpublished data). The 
frequency of autoantigen recognition within the EBNA1-
specifi  c T cell compartment did not diff  er signifi  cantly be-
tween patients and controls (  Fig. 5 B  ). 
  We next determined the cytokine profi  le of 10 myelin 
cross-recognizing and 30 EBNA1-monospecifi  c T cell clones 
from individuals in whom we could detect cross-recognition. 
Among all cytokines tested (  n   = 25), myelin cross-recogniz-
ing T cells diff  ered substantially from their monospecifi  c 
counterparts in their ability to produce high amounts of IL-2 
(P   <   0.0001) and in their inability to produce certain eff  ector 
cytokines implicated in antiviral defense, such as the antiviral 
C-C (    ) chemokine macrophage infl  ammatory protein-1     
(MIP-1    ; P = 0.02;   Fig. 5 D  ). IFN-     was detected in both 
subsets. These data indicate that the expanded EBNA1-spe-
cifi  c CD4  +   T cell repertoire in MS shows two distinct func-
tional signatures, and that the myelin-reactive population can 
be distinguished by its ability to produce large amounts of 
IL-2 and less MIP-1     and -1    . 
  Concluding remarks 
  In healthy individuals, elevated IgG titers to EBNA1, but not 
to EBNA2, EBV-encoded early antigens, the viral capsid 
  antigen, or other lytic antigens, are the strongest predictor of 
MS risk (  2, 6  ). The presence of oligoclonal IgG in the cere-
brospinal fl  uid is a hallmark of MS, and the two most fre-
quent MS-specifi  c and high-affi   nity epitopes recognized by 1770 EBV IMMUNITY IN MULTIPLE SCLEROSIS   | L  ü  nemann et al. 
spots compared with rVV-TK       . Frequencies of T cells specifi  c for rVV were 
calculated by subtracting the mean spot number of rVV-TK         –  stimulated 
cells from the EBV antigen-rVV  –  stimulated wells. 
  Western blot.     To determine EBNA1 protein expression in rVV-
EBNA1    GA  –  infected PBMCs, 5   ×   10  6   PBMCs were infected with rVV-
EBNA1    GA or mock infected at a MOI of 10 for 16 h. Samples were 
boiled for 30 min in Laemmli sample buff  er (BioRad Laboratories). A re-
combinantly expressed fusion protein consisting of the C terminus of EBNA1 
(aa 400  –  641) coupled to the heavy chains of an antibody, which was available 
in our laboratory, was used as a positive control. Proteins from 1.25   ×   10  6   
PBMCs were separated on 7.5% SDS-PAGE gels and, after blotting, stained 
with the EBNA1-specifi  c mouse monoclonal Ab 5F12. HRP-coupled goat 
IgG (BioRad Laboratories) was used as secondary antibody. Western blots 
were developed using the ECLplus kit (GE Healthcare). 
  Antigens.     51 peptides covering the C-terminal of EBV nuclear antigen 1 
(aa 400  –  641), 147 peptides covering the entire sequence of the HCMV-en-
coded pp65 protein (aa 1  –  561), and 28 peptides covering the entire sequence 
of the human proinsulin precursor protein (aa 1  –  110) were purchased from 
the Proteomics Resource Center of the Rockefeller University (Table S3) 
(  9, 14  ). In addition, we included 15 peptides derived from 4 major myelin 
proteins. MBP, proteolipid protein, myelin oligodendrocyte glycoprotein, 
and 2    ,3    -cyclic nucleotide 3     phosphodiesterase were selected based on 
careful literature review as immunodominant in humans and/or encephali-
togenic in animals (Table S3) (  25  ). Infl  uenza A virus (A/Aichi/68, H3N2; 
Charles River Laboratories) infection and   C. albicans   (Greer Laboratories) 
served as additional controls. 
  Flow cytometry.     PBMCs were isolated from blood samples via density 
centrifugation. PBMCs were washed in PBS and incubated at 37  °  C in 
0.3   μ  M CFSE (Invitrogen) in PBS at a concentration of 10  7   cells per ml for 
10 min. Cells were washed in PBS and resuspended in 5% PHS with 1   μ  g/ml 
co-stimulatory monoclonal antibodies to CD28 and CD49d (BD Biosci-
ences) at a concentration of 1.7   ×   10  6   cells per ml. PBMCs were distributed 
at 1 ml or 1.7   ×   10  6   cells per well into 48-well plates. Cells were stimulated 
with the respective pools of peptides with a fi  nal concentration of 3.5   μ  mol 
per EBNA1-peptide and 5   μ  mol of the HCMV-pp65  –  derived antigens. 
  Staphylococcus   enterotoxin B (SEB; Sigma-Aldrich) was additionally used as a 
positive control at a fi  nal concentration of 125 ng/ml. At the conclusion of 
a 6-d incubation at 37  °  C and 5% CO  2  , cells were harvested and washed once 
in PBS and stained with a combination of directly fl  uorochrome-labeled an-
tibodies against CD3, CD4, CD62L, CD27, CD28, and CXCR3 (BD Bio-
sciences) for 30 min at 4  °  C. The cells were washed once with PBS and 
resuspended in 200   μ  l FACS buff  er (0.01% sodium azide in PBS) before 
FACS analysis. The samples were analyzed on an LSR II fl  ow cytometer 
gating on lymphocytes based on size and on being CD3  +  . Responses were 
considered positive if the frequency of CFSE  low   T cells in peptide-stimulated 
cultures exceeded those from unstimulated cultures by at least twofold. Fre-
quencies were calculated by subtracting background events (without anti-
gen) from events in antigen-stimulated samples. Gating and calculations for 
precursor frequencies were performed with FlowJo (Tree Star, Inc.) soft-
ware. To determine the frequency of IL-17  –  producing antigen-specifi  c T 
cells, CFSE-stained PBMC were stimulated with pooled   C. albicans   antigens 
(Greer Laboratories) at a concentration of 40   μ  g/ml, or with EBNA1 or with 
SEB. After 7 d, the cells were stimulated with PMA (10 ng/ml) and ionomy-
cin (10 mg/ml) for 24 h, whereas monensin (2   μ  M) was added for the last 12 
h of incubation. The frequency of antigen-specifi  c Th17 cells was determined 
by gating on the CD3  +  CD4  +   CFSE  low   population and using a monoclonal 
PE-coupled IL-17 antibody (eBioscience). To determine the clonality of myelin 
cross-reactive, EBNA1-specifi  c T cells, growing T cell cultures were charac-
terized by staining with a panel of 22 anti-TCR V     fl  uorescein-conjugated 
antibodies recognizing TCR-V    3, -V    1, -V    5S1, -V    2, -V    5S2, -V    5S3, 
-V    6S7, -V    7, -V    8, -V    9, -V    11, -V    13S1, -V    12, -V    13S6, -V    16, 
-V    14, -V    17, -V    18, -V    21S3, -V    20, -V    22, and -V    23 (Immunotech), as 
CD4  +   T cells, we are still far from understanding the mecha-
nisms leading to disease development and progression. Further 
investigations will be necessary to clarify whether targeting EBV 
and EBV-specifi  c immune compartments may become ther-
apeutic options in MS. 
    MATERIALS AND METHODS   
  Patients and healthy donors.     24 untreated MS patients (23 with clinically 
defi  nite, and 1 with clinically isolated demyelinating syndrome fulfi  lling the 
revised   “  McDonald  ”   criteria for diagnosing MS) and 24 age-, sex-, and 
MHC class II  –  matched healthy donors were enrolled to study EBV-specifi  c 
T cell responses (Table S1). Patients and controls were recruited from the 
New York blood bank and the Department of Neurology and Institute for 
Neuroimmunology and Clinical MS research, University Medical Center 
Hamburg-Eppendorf, Germany. Additional patients and controls were re-
cruited form the Department of Neurology at the Phillips University of 
Marburg, Germany. All individuals were infected by EBV as assessed by pos-
itive IgG antibody titers against EBV-encoded viral capsid antigen. The 
study was approved by the local Institutional Review Boards (Ethics Com-
mittees of the Medical Faculties of the Universities of Hamburg and Mar-
burg and the Institutional Review Board of the Rockefeller University), and 
all subjects provided informed consent. 
  rVVs.     rVVs were expanded in rabbit RK13 and titrated on monkey BSC40 
kidney cells, as previously described (  11  ). PBMCs were infected at a multi-
plicity of infection (MOI) of 10, incubated in ELISPOT plates for 48 h at 
37  °  C, and washed three times. The effi   ciency of infection was checked after 
24 h by intracellular staining with a monoclonal PE-coupled antibody specifi  c 
for LMP1 (BD Biosciences) by fl  ow cytometry. We observed that 10  –  15% 
of PBMCs became infected with rVV. If the light scatter gate was set on 
the monocyte fraction, 60  –  85% of the cells stained positively for LMP-1. 
LMP-1 staining was done in more than half of the experiments (the others 
were limited by small cell numbers) to verify that diff  erences in the number 
of IFN-     spots were not caused by variable rates of rVV infection. Samples 
derived from patients and healthy donors were consistently tested on the 
same plate to minimize the bias of plate to plate variations. ELISPOT assays 
were reproducible because the same results were obtained, if cryopreserved 
samples from healthy donors were tested on more than one occasion. The 
following rVVs expressing EBV latent antigens were used: rVV-TK        (nega-
tive control), rVV-BZLF1, rVV-EBNA3A, rVV-EBNA3B, rVV-EBNA 3C, 
rVV-LMP1, rVV-LMP2a, and rVV-EBNA1    GA (deleted of Gly-Ala repeat). 
Infl  uenza A virus (A/Aichi/68; H3N2) was used at 50,000 HAU/ml and 
purchased from Charles River Laboratories.   Staphylococcus   enterotoxin B 
(Sigma-Aldrich) was additionally used as a positive control at a fi  nal concen-
tration of 125 ng/ml. 
  ELISPOT for IFN-     release.     96-well plates (Millititer; Millipore) were 
coated overnight at 4  °  C with 10 mg/ml of the primary anti-IFN-     mAb 
(Mabtech). The antibody-coated plates were washed four times with PBS 
and blocked with RPMI containing 5% PHS for 1 h at 37  °  C. 2   ×   10  5   
PBMCs in 100   μ  l culture medium containing 1% human AB serum were 
added per well and infected with rVV in triplicates. Cells were incubated for 
24 h at 37  °  C in 5% CO  2  . Wells were washed four times with PBS contain-
ing 0.05% Tween-20 (Sigma-Aldrich), followed by a 2-h incubation with 
50   μ  l of the secondary antibody (1 mg/ml biotin-conjugated anti-IFN-     
mAb; Mabtech). Plates were washed four times in PBS with 0.1% Tween-
20. Avidin-bound biotinylated horseradish peroxidase H (Vectastain Elite 
kit; Vector Laboratories, Inc.) was added to the wells for 1 h at room tem-
perature. The plates were washed four times in PBS with 0.1% Tween-20, 
followed by a 5-min incubation in stable diaminobenzene (Research Ge-
netics) to develop the reaction; tap water was added to stop the reaction. The 
spots were counted with an ELISPOT reader (AID Autoimmun Diagnostika 
GmbH). Only spots with a fuzzy border and a brown color were counted. 
A response was considered positive if there was at least twice the number of JEM VOL. 205, August 4, 2008  1771
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resuspended and half of the total volume (100   μ  l) was transferred into new 
plates, which were pulsed with   3  H-thymidine (GE Healthcare) for 16 h at 
1   μ  Ci/well. T cell medium enriched with 10 IU/ml IL-2 was added to the re-
maining nonpulsed wells to propagate the cultures. The incorporated radio-
activity (cpm) in   “  daughter  ”   plates was measured by scintillation counting 
(1450 Microbeta; Wallac/PerkinElmer Life Sciences). Individual wells were 
considered positive if their stimulation index (SI = cpm of wells with anti-
gen/mean cpm of 10 negative control wells) was   >  2. Positive cultures were 
identifi  ed on the corresponding   “  mother  ”   plates and restimulated on day 10 
with 10  5   autologous irradiated antigen-pulsed (1   μ  M per peptide) PBMCs. 
IL-2 (10 U/ml) and IL-7 (10 ng/ml)-enriched medium was added on day 11, 
and again 5 d later. After 12 d of expansion, 4   ×   40   μ  l of a total of 200   μ  l 
were transferred to a new daughter plate and stimulated with EBNA1, mye-
lin antigens, and PIP-derived antigens (1   μ  M per peptide) or without antigen 
(negative control).   3  H-thymidine was added 40 h later at 1   μ  Ci/well, and 
cells were harvested 60 h after stimulation (day 25). Again, individual wells 
were considered positive if SI was   >  2. T cell cultures identifi  ed as cross-reactive 
were restimulated once with EBNA1 peptides in the presence of autologous 
feeders and 20 IU/ml IL-2 and analyzed for TCR V     expression after 8  –  14 d. 
Precursor frequencies of cross-reactive and non  –  cross-reactive TCLs were 
determined by the number of positive wells compared with number of 
seeded cells in single precursor plates, which were restimulated after primary 
proliferation. Corresponding positive cultures on the mother plate were re-
stimulated with autologous feeders and further expanded in the presence of 
20 IU/ml IL-2. 
  Luminex assay.     Cell supernatants from cultures obtained from myelin anti-
gen-reactive and only EBNA1-specifi  c T cells were analyzed at day 1 after 
the second restimulation for cytokines and using the human cytokine 25-
plex antibody bead kit (Invitrogen/Biosource) as per the manufacturer  ’  s pro-
tocol. This kit comprises analyte specifi  c components for the quantifi  cation 
of the following 25 cytokines and chemokines: IL-1    , IL-1ra, IL-2, IL-2R, 
IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-13, IL-15, IL-17, TNF-    , 
IFN-    , IFN-    , GM-CSF, MIP-1    , MIP-1    , IP-10, MIG, Eotaxin, RANTES, 
and MCP-1. Multiplex beads were vortexed and sonicated for 30 s, and 
25   μ  l was added to each well and washed two times with wash buff  er. The 
samples were diluted 1:1 with assay diluent and loaded onto a Multiscreen 
BV 96-well fi  lter plate (Millipore) with 50   μ  l of incubation buff  er already 
added to each well. Serial dilutions of cytokine standards were prepared in 
parallel and added to the plate. Samples were then incubated on a plate shaker 
at 600 rpm in the dark at room temperature for 2 h. The plate was applied to 
a Multiscreen Vacuum Manifold (Millipore) and washed twice with 200   μ  l 
of wash buff  er. 100   μ  l of biotinylated anti  –  human Multi-Cytokine Reporter 
(Biosource International) was added to each well. The plate was incubated 
on a plate shaker at 600 rpm in the dark at room temperature for 1 h. The 
plate was applied to a Multiscreen Vacuum Manifold and washed twice with 
200   μ  l of wash buff  er. Streptavidin-phycoerythrin was diluted 1:10 in wash 
buff  er, and 100   μ  l was added directly to each well. The plate was incubated 
on a plate shaker at 600 rpm in the dark at room temperature for 30 min. The 
plate was then applied to the vacuum manifold, washed twice, and each well 
was resuspended in 100   μ  l wash buff  er and shaken for 1 min. The assay plate 
was then transferred to the Bio-Plex Luminex 100 XYP instrument 
(Millipore) for analysis. Cytokine concentrations were calculated using Bio-
Plex Manager 3.0 software with a 25-parameter curve-fi  tting algorithm ap-
plied for standard curve calculations. 
  Statistical analysis.     Statistics were performed using commercial software 
(PRISM 4; GraphPad Software). Comparisons between MS patients and 
healthy donors are based on the nonparametric Mann-Whitney U rank sum 
test. Categorial analyses were performed using Fisher  ’  s exact test. To correct 
for multiple testing, i.e., IFN-    responses to BZLF1, EBNA1   GA, EBNA2, 
EBNA3A, EBNA3B, EBNA3C, LMP1, LMP2A, and infl  uenza infection, 
the conservative Bonferroni correction was 0.05/9 = 0.0055. Consequently, 
P   <   0.0055 was considered signifi  cant and 0.05   >   P   >   0.0055 was a sta-
tistical trend. 
well as CD4 and CD8 monoclonal antibodies (Beckman Coulter). Fluorescence 
intensity was measured on an LSR II fl  ow cytometer and analyzed with FlowJo 
(Tree Star, Inc.) software. 
  ELISA and expression and purifi  cation of recombinant EBNA1.   
  HCMV-EA (early antigen)  –  specifi  c antibodies were detected with a com-
mercial ELISA kit following the manufacturer  ’  s recommendations using 
predetermined cut-off   values based on the manufacturer  ’  s criteria (Bio-
Quant, Inc.). The C-terminal domain of EBNA1 (aa 458  –  641) inserted in 
the expression vector pET15b (Novagen) was transfected into   Escherichia 
coli   BL21 (DE3) pLysS cells and expression was induced with 1 mM IPTG 
(Invitrogen). The protein was purifi  ed, and the identity was determined 
by Western blot analysis with EBNA1-specifi  c  antibody  (MAB8173; 
Chemicon International). Standardized lysates of EBV-infected B cells and 
noninfected control B cells were obtained from EastCoast Bio. 96-well 
polystyrene plates (Thermo Fisher Scientifi  c) were coated with 1   μ  g/well 
of rEBNA1 protein in PBS, or infected and noninfected cell lysates, or PBS 
alone overnight at 4  °  C. Plates were blocked with 200   μ  l/well 5% nonfat 
milk powder for 30 min, followed by 30 min in PBS containing 5% BSA. 
Test plasma samples, diluted 1:10, 1:100, 1:200, 1:500, 1:1,000, and 1:2,000 
in 3% BSA, were added for 30 min at room temperature. Plates were 
washed three times with TBST (10 mM Tris, 140 mM NaCl, and 0.05% 
Tween 20). Biotin mouse anti  –  human IgG1, IgG2, and IgG3 antibodies 
(BD Biosciences) were added at 1:1,000, and the anti  –  human IgG4 anti-
body was added at 1:5,000 in TBST for 30 min at room temperature. After 
the plates were washed three times in TBST, avidin-bound biotinylated 
HRP was added for 20 min at room temperature, followed by TMB 
  substrate (R  &  D Systems) to develop the reaction for 10 min at room tem-
perature and 1 M H  2  SO  4   to stop the reaction. Plates were read in a micro-
plate reader (Dynex Technologies). Samples were processed blinded to 
the clinical diagnosis. Sample ODs from noninfected control cell lysates 
were subtracted from ODs from EBV-infected cell lysates. Titers were 
defined by the 10% effect concentration (EC  10  ) value of individual titra-
tion curves. 
  Regression assay.     B cells were isolated by positive selection using CD19-
Microbeads (Miltenyi Biotec). The negative fraction (CD19       ) was plated in 
48-well plates in increasing cell concentrations (0, 1   ×   10  5  , 0.5   ×   10  5  , 10  5  , and 
5   ×   10  5  ) in duplicates. 5   ×   10  6   CD19  +   cells per donor were infected overnight 
at 37  °  C and in 5% CO  2   with supernatant of the EBV  +   marmoset cell line 
B95-8 cultured for 12 d in RPMI-1640 containing 10% FCS and gentamycin 
without refeeding. Virus-containing supernatant was centrifuged at 2,000 rpm 
for 10 min and passed through a 0.45-  μ  m fi  lter. The same supernatant was 
used to infect B cells from both patients with MS and healthy blood donors. 
After 24 h, EBV-infected B cells were washed twice and added to CD19- cells 
at eff  ector to target ratios of 1:1, 1:5, 1:10, and 1:50. After 12 d, transformation 
and regression of transformed B cells were quantifi  ed by determining the ratio 
of CD19  +   CD23  +   cells to live CD19  +   B cells by fl  ow cytometry. Samples 
were analyzed on an LSR II fl  ow cytometer. Gating and calculations were 
performed with FlowJo (Tree Star, Ashland, OR) software. 
  T cell cross-recognition.     To obtain single-cell, EBNA1-specifi  c T cell 
precursors, we adapted a modifi  ed limiting dilution protocol that has initially 
been described for mixed lymphocyte cultures (  24  ). The experimental setup 
for this assay is outlined in Fig. S5. PBMCs were isolated from blood samples 
via density centrifugation and seeded in increasing cell concentrations of 
0.125   ×   10  5  , 0.25   ×   10  5  , and 0.5   ×   10  5   cells per well together with autolo-
gous irradiated (3,000 rad) feeder cells resulting in a total cell number of 10  5   
per well in 96-well U-bottom microtiter plates in T cell medium (RPMI; 
Invitrogen) containing 2 mM   l-  glutamine, 50   μ  g/ml gentamicin, and 100 
U/ml penicillin/streptomycin (all from Whittacker Bioproducts), and 5% 
pooled human AB serum, and enriched with 10 ng/ml IL-7 (PeproTech). 
50 wells were stimulated with EBNA1 peptides (aa 400  –  641), and 10 wells 
did not receive any antigens. All peptides were used at a fi  nal concentration 
of 1   μ  M. After 7 d of incubation at 37  °  C and in 5% CO  2  , each culture was 1772 EBV IMMUNITY IN MULTIPLE SCLEROSIS   | L  ü  nemann et al. 
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